A.P. inks pact with AstraZeneca to set up Genomic Solutions Centre in Amaravati
Andhra Pradesh has partnered with AstraZeneca India to establish an Integrated Genomic Solutions Centre in Amaravati for advanced cancer research and treatment. The project will utilize AI and next-generation sequencing to provide personalized oncology care.
Why it matters
This initiative represents a significant integration of AI and genomic technology into public healthcare infrastructure in India.
Andhra Pradesh on Tuesday signed a Memorandum of Understanding (MoU) with AstraZeneca India to establish an Integrated Genomic Solutions Centre in Amaravati, marking a major step towards precision cancer care. The initiative aims to create India's first integrated precision oncology research and treatment ecosystem, enabling personalised cancer diagnosis and treatment through advanced genomic technologies.
The MoU was exchanged between the State government and AstraZeneca India in the presence of Chief Minister N. Chandrababu Naidu. The collaboration will also involve Reliance-backed Strand Life Sciences and Qure.ai.
The centre will provide advanced genomic testing and biomarker analysis for patients with lung and breast cancers. It will use next-generation sequencing (NGS), artificial intelligence (AI), and genomic technologies to facilitate early cancer detection and recommend personalised treatment based on a patient's genetic profile.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in